Categories Earnings, Health Care

Sanofi (NASDAQ: SNY): Q4 2019 Earnings Snapshot

— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018.

— Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34.

— IFRS net sales, on a reported basis, increased 6.8% year-over-year to EUR 9.61 billion.

— Sanofi Genzyme sales rose 19.7% annually, aided by strong growth of 135% in Dupixent global sales.

— Vaccine sales increased 22%, reflecting majority of U.S. influenza vaccine shipments in Q4.

— CHC sales down 5.2%, mainly due to Zantac voluntary recall, non-core divestments and changing regulatory requirements.

— For FY20, Sanofi expects business EPS to grow about 5%, at constant exchange rates.

— SNY stock was up about 4% in the pre-market trading session.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Tyson Foods (TSN) Q1 2023 Earnings: Key financials and quarterly highlights

Tyson Foods Inc. (NYSE: TSN) reported first quarter 2023 earnings results today. Sales rose 2.5% year-over-year to $13.2 billion. Net income attributable to Tyson was $316 million, or $0.88 per

After weak start to 2023, Apple (AAPL) sees some bright spots

Apple Inc. (NASDAQ: AAPL) this week reported its first revenue decline in more than three years, even as the high inflation continues to squeeze customers’ spending power. Sales of the

Earnings: Qualcomm (QCOM) Q1 profit falls on lower revenues

Chipmaker Qualcomm, Inc. (NASDAQ: QCOM) has reported lower earnings and revenues for the first quarter of 2023. The company also provided guidance for the second quarter of 2023. At $9.5

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top